Viking Global Sells 1.28M BridgeBio Shares, Stake Drops Below 5%
BBIO has more than doubled off its 52-week low of $42.09.
Summary
Viking Global Investors sold 1.28 million shares of BridgeBio Pharma, reducing its stake to 4.9951% and crossing below the 5% reporting threshold. Total proceeds were approximately $90.5 million.
Key Events · Ownership and Investor Activity · BBIO
-
Viking Global Sells 1.28M Shares
Between May 22 and July 9, 2026, Viking Global Investors and affiliates sold 1,282,822 shares of BridgeBio Pharma common stock, reducing their aggregate ownership to 9,792,219 shares (approximately 4.9951% of outstanding shares).
-
Stake Falls Below 5% Threshold
As of July 9, 2026, the reporting persons ceased to be beneficial owners of more than 5% of the shares of Common Stock, triggering this Schedule 13D/A filing.
-
Sales Total ~$90.5 Million
The shares were sold at prices ranging from $66.09 to $90.40 per share, with total proceeds of approximately $90.5 million. The sales were executed in multiple open-market transactions.
-
Context: Strong Positive News Flow
The sales occurred during a period of significant positive developments for BridgeBio, including FDA priority review for BBP-418, positive Phase 3 data for acoramidis, and a $1 billion convertible preferred equity financing.
Analysis · BBIO · Life Sciences
A major institutional holder, Viking Global Investors, sold over 1.28 million shares of BridgeBio Pharma between May and July 2026, reducing its stake from above 5% to approximately 4.9951%. The sales, totaling roughly $90.5 million, were executed at prices ranging from $66.09 to $90.40 per share. This marks a significant reduction by a long-time investor and comes amid a period of strong positive clinical and regulatory news for the company, including FDA priority review for BBP-418 and a $1 billion convertible preferred equity financing. The exit from the 5% reporting threshold could signal a shift in conviction or portfolio rebalancing, though the sales were spread over several weeks and at rising prices, suggesting orderly disposition rather than panic selling.
At the time of this filing, BBIO was trading at $85.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.8B. The 52-week trading range was $42.09 to $93.42. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.